Based on the anti-inflammatory function of MaR1 and Prdx5 in vitro, we investigated whether MaR1 treatment or Prdx5 deficiency influenced the severity of MSU crystal-induced gouty arthritis in vivo. This evidence concerns the gene PRDX5 and gout.